XXXX and @entity1499 for advanced bladder cancer.

@entity1 @entity1499 @entity5 @entity5713
Fifty-seven @entity1 with advanced measurable urothelial tract @entity5 , 52 of whom had an adequate trial, were treated weekly with 3 to 4 mg. per m.2 vinblastine and 30 to 40 mg. per m.2 @entity1499 . Of 3 @entity1 with unidimensional parameters 2 showed improvement lasting 16 and 27 months, which was documented by serial cystoscopic examinations. An additional 2 @entity1 had measurable disease that could have been encompassed in a preoperative radiotherapy field. Both @entity1 are free of disease at more than 12 and 14 months, respectively. Of the 47 @entity1 with bidimensionally measurable parameters 19 (40 per cent) achieved a complete or partial remission lasting a median of 8 months, with a range of 1 to 24 months. Of 25 @entity1 with intra-abdominal or pelvic disease 7 achieved a complete or partial remission and 5 also had a minor remission. Of note, 18 of 38 @entity1 who had received no prior chemotherapy achieved a remission versus 1 of 9 who had been treated previously (p equals 0.06). Responders frequently obtained another remission with subsequent chemotherapy (4 of 9 versus 0 of 16, p equals 0.03). Responders lived 14 months versus 8 months for nonresponders (p equals 0.02). Four responders had brain metastases compared to none of 28 nonresponders. The combination of @entity5713 and @entity1499 is a well tolerated, effective outpatient regimen for @entity1 with urothelial tract @entity5 .
